Cardiff Oncology to Present at Key Oncology and Investment Conferences in September 2026
Event summary
- Cardiff Oncology's CEO, Mani Mohindru, Ph.D., to present at two conferences in September 2026.
- Presentations include the 8th Annual RAS-Targeted Drug Development Summit on September 8 and the H.C. Wainwright 28th Annual Global Investment Conference on September 14.
- Slides and webcast replays will be available on Cardiff Oncology's website post-events.
- Cardiff Oncology focuses on PLK1 inhibition for cancer treatments, with lead asset onvansertib in Phase 2 trials for RAS-mutated metastatic colorectal cancer.
The big picture
Cardiff Oncology's participation in these conferences underscores the growing interest in targeted cancer therapies, particularly those addressing high-unmet needs like RAS-mutated metastatic colorectal cancer. The presentations come at a critical time as the company advances its lead asset, onvansertib, through Phase 2 trials. Success in these trials could position Cardiff Oncology as a key player in the oncology space, attracting both investor attention and potential strategic collaborations.
What we're watching
- Clinical Progress
- How the Phase 2 trial results for onvansertib in RAS-mutated metastatic colorectal cancer will impact investor sentiment and strategic partnerships.
- Market Positioning
- Whether Cardiff Oncology can differentiate itself in the competitive landscape of targeted cancer therapies.
- Investor Interest
- The level of interest and potential funding opportunities arising from the H.C. Wainwright conference.
Related topics